ClinicalTrials.gg

TargetBeta

AR

androgen receptor · also AIS, NR3C4, SMAX1, HUMARA · Nuclear receptor subfamily 3 group C

16 programs in company-led studies act on AR, from 12 companies: 5 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
apalutamideruleJohnson & Johnsonphase 43113 running–NCIt
enzalutamideruleAstellas Pharmaphase 46912 running–NCIt
darolutamideruleBayerphase 4268 running–NCIt
ClascoteroneruleCassiopea SpAphase 4193 running–ChEMBL
rezvilutamideruleJiangsu HengRui Medicinephase 3133 running–NCIt
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 333 runningBRD4a judged reading
Cyproterone AcetateruleEurofarma Laboratoriosphase 342 runningNR3C1, PGRChEMBL
ostarineruleGTxphase 3151 running–ChEMBL
dezandrodegruleBristol-Myers Squibbphase 351 running–NCIt
HRS-5041Jiangsu HengRui Medicinephase 264 running–the company's pipeline
luxdegalutamideNovartisphase 233 running–the company's pipeline
luxdegalutamideNovartisphase 222 running–the company's pipeline
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 211 running–NCIt
Androgen Receptor Degrader GSK5471713GlaxoSmithKlinephase 211 running–the company's pipeline
TQB3201Sino Biopharmaceuticalphase 211 running–the company's pipeline
Androgen Receptor Antagonist TQB3720Sino Biopharmaceuticalphase 110 running–the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.